Skip to main content

Table 2 Summary of health state cost and utility inputs

From: Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

Health state

Cost (2012/13 £)

Utility

Source

Mean (SE)

Mean (SE)

Fibrosis stages

 F0

177.47 (35.01)

0.77 (0.015)

[21]

 F1

177.47 (35.01)

0.77 (0.015)

 F2

922.08 (97.82)

0.66 (0.031)

 F3

922.08 (97.82)

0.66 (0.031)

 F4 (compensated cirrhosis)

1463.50 (297.45)

0.55 (0.054)

SVR

 SVR from F0 to F1

333.08 (62.05)

0.82 (0.043)

[21]

 SVR from F2 to F3

922.08 (97.74)

0.72 (0.048)

 SVR from F4 (compensated cirrhosis)

1463.50 (288.07)

0.72 (0.048)a

ESLD

 Decompensated cirrhosis

11,728.61 (1954.09)

0.45 (0.031)

[21]

 HCC

10,451.58 (2456.09)

0.45 (0.031)

 Liver transplant (transplant cost)

35,147.26 (3709.93)

NA

 Liver transplant (cost of care: initial year)

12,163.29 (3133.55)

0.45 (0.031)

 Liver transplant (subsequent years)

1781.15 (456.57)

0.67 (0.066)

  1. HCC hepatocellular carcinoma, NA not applicable, SE standard error, SVR sustained virologic response, ESLD end stage liver disease
  2. aAssumption, based on SVR from F2 to F3